MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice

In oncology, the occurrence of distant metastases often marks the transition from curative to palliative care. Such outcome is highly predictable for breast cancer patients, even if tumors are detected early, and there is no specific treatment to prevent metastasis. Previous observations indicated t...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-03, Vol.14 (6), p.1488
Main Authors: Capeloa, Tania, Krzystyniak, Joanna, Rodriguez, Amanda Canas, Payen, Valéry L, Zampieri, Luca X, Pranzini, Erica, Derouane, Françoise, Vazeille, Thibaut, Bouzin, Caroline, Duhoux, François P, Murphy, Michael P, Porporato, Paolo E, Sonveaux, Pierre
Format: Article
Language:English
Subjects:
Alzheimer's disease
Antioxidants
Apoptosis
Biodistribution
Breast cancer
Cancer therapies
Chemotherapy
Clinical trials
Drug dosages
Growth factors
Lung cancer
Lungs
Melanoma
Metabolism
Metastases
Metastasis
Mitochondria
Patients
Progenitor cells
Stem cells
Superoxide
Surgery
Tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In oncology, the occurrence of distant metastases often marks the transition from curative to palliative care. Such outcome is highly predictable for breast cancer patients, even if tumors are detected early, and there is no specific treatment to prevent metastasis. Previous observations indicated that cancer cell mitochondria are bioenergetic sensors of the tumor microenvironment that produce superoxide to promote evasion. Here, we tested whether mitochondria-targeted antioxidant MitoQ is capable to prevent metastasis in the MDA-MB-231 model of triple-negative human breast cancer in mice and in the MMTV-PyMT model of spontaneously metastatic mouse breast cancer. At clinically relevant doses, we report that MitoQ not only prevented metastatic take and dissemination, but also local recurrence after surgery. We further provide in vitro evidence that MitoQ does not interfere with conventional chemotherapies used to treat breast cancer patients. Since MitoQ already successfully passed Phase I safety clinical trials, our preclinical data collectively provide a strong incentive to test this drug for the prevention of cancer dissemination and relapse in clinical trials with breast cancer patients.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14061488